Feeds:
Posts
Comments

Posts Tagged ‘androgen-deprivation therapy’

URO TODAY: New drugs – still being trialled – are proving effective treatment of prostate cancer bone metastases and prevention of fractures associated with androgen deprivation therapy. READ MORE>

Read Full Post »

URO TODAY: Acupuncture provides excellent control of hot flashes in men undergoing androgen ablation therapy (hormone treatment) for prostate cancer, according to US researchers. READ MORE>

Read Full Post »

URO TODAY: The recovery of testosterone after long-term androgen deprivation therapy for prostate cancer is slow, according to a study of about 20 patients who had been receiving hormone drugs for a mean seven years. READ MORE>

Read Full Post »

URO TODAY: A fracture-reducing drug called toremifene has a useful side effect when used on prostate cancer patients – it significantly reduces hot flushes caused by hormone therapy. READ MORE>

Read Full Post »

URO TODAY: Once, chemotherapy (then death) were the only options left for prostate cancer patients on whom hormone therapy stopped working: now new drugs give hope of extended life. READ MORE>

Read Full Post »

URO TODAY: It’s very early days, but medical scientists in Israel may have made a new discovery about the cause of prostate cancer and subsequently how to treat it. READ MORE>

They believe that as men age, very highly concentrated testosterone leaks to the prostate gland via the testicular and prostate venous (blood) drainage systems.

They tried treating six men with an “interventional radiological procedure and super-selective intraprostatic androgen deprivation therapy” and in five cases achieved a decrease in prostate size and in PSA levels, with repeat biopsies showing disappearance of cancerous cells.

The work is being done at Maynei Hayeshua medical center and Department of Condensed Matter Physics, Weizmann Institute of Science, Rehovot, Israel.

At NEW PROSTATE CANCER INFOLINK, Mike Scott writes:

This is clearly a radical new finding that needs to be confirmed by other research groups.

Should it prove to be accurate, we may have a whole new mechanism available to treat early stage disease without having to expose patients to systemic forms of hormone therapy.

The “New” Prostate Cancer InfoLink emphasizes, however, that we have seen only an abstract of this report, and we need greater detail to understand what is actually being suggested by Gat and colleagues. READ MORE>

Read Full Post »

URO TODAY: Testicular prostheses that slow-release drugs to combat bone loss in men being treated for advanced prostate cancer, have the potential to restore testes removal as a viable option for testosterone control. READ MORE>

Read Full Post »

URO TODAY: High levels of testosterone have until recently been regarded as dangerous for prostate cancer patients, but new evidence is emerging that suggests something different. READ MORE>

Provocative new evidence suggests that it is not high serum testosterone that is problematic for prostate cancer, but low serum testosterone that is associated with worrisome cancer features and outcomes, such as high Gleason score, advanced stage of presentation, and increased risk of biochemical recurrence after surgery.

Read Full Post »

URO TODAY: Younger men with high-risk prostate cancer appear to have worse prognosis than older men with similar disease, according to a study of 4000 men receiving hormone treatment. READ MORE>

This, along with the other prognostic variables established in the current study, may help identify candidates for clinical trials evaluating secondary treatments for patients with castrate-resistant disease.

Read Full Post »

URO TODAY: Enzymes in the prostate that promote aggressive cancer growth need to be suppressed and a study looks at the success of new drugs now available to do the job. READ MORE>

The objective of this review is to provide an understanding of the pharmacological properties and the potential clinical benefits of 5AR inhibition.

The efficacy of 5AR2 monotherapy with finasteride alone or in combination with an androgen receptor antagonist on more final outcome measures seems to be limited.

Combining an androgen receptor antagonist with a 5AR inhibitor in patients with asymptomatic, locally advanced or recurrent prostate cancer might be a reasonable first therapeutic hormonal approach.

5-alpha reductase is an enzyme that converts testosterone, the male sex hormone, into the more potent dihydrotestosterone:

Read Full Post »

Older Posts »